Cabazitaxel XRP6258

Phase 2

Sanofi (SNY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

NCT01511536

Last updated: 12/8/2025

Regulatory Approvals

EMAPending

Cabazitaxel Teva

Treatment of prostate cancer

View on EMA

EMA8/28/2020

Cabazitaxel Accord

Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

View on EMA

EMA3/17/2011

Jevtana

Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

View on EMA

Developer

SNY

Sanofi

Biotechnology•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline